Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Agilent Technologies Inc announces new study reinforces major advantages of Dako's HER2 IQFISH pharmDx in Breast Cancer Diagnostics


Friday, 14 Feb 2014 09:11am EST 

Agilent Technologies Inc:Says positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx.Says the Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology.Says that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer.Says Dako introduced the cutting-edge IQFISH hybridization buffer chemistry in 2012.Says the IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours.Says more than 1.5 mln new cases of breast cancer are diagnosed each year worldwide.Says as an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor.Says the study concludes that the highly concordant results (99.3 pct) and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status.Says it also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever. 

Company Quote

54.32
-0.18 -0.33%
30 Oct 2014